FDG PET/CT of the non‐malignant liver in an increasingly obese world population
Clinical Physiology and Functional Imaging · 2020-09 · 40 (5) · 304-319
DOI: 10.1111/cpf.12651 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Physiology and Functional Imaging, online erschienen am 15.07.2020. Verfasst von Georgia Keramida und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Royal Brompton and Harefield, NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 112 Literaturangaben.
Abstract (Originalsprache)
Because of obesity, non‐alcoholic fatty liver disease (NAFLD) is becoming increasingly important. 10% of NAFLD patients develop non‐alcoholic steatohepatitis (NASH), which may progress to cirrhosis and is now the leading indication for liver transplantation in the Western world. Prefibrotic NASH can only be reliably diagnosed by biopsy. However, given its success in other inflammatory diseases, PET/CT with 18 F‐fluorodeoxyglucose (FDG), although non‐specific, may offer a promising approach to diagnosing not only NASH but also other inflammatory liver conditions. In addition, FDG PET has generated pathophysiological information on hepatic glucose metabolism and, diagnostically, used liver for quantification of tumour FDG accumulation (e.g. Deauville scoring). A review of hepatic FDG PET is therefore timely. There are two general approaches to the quantification of hepatic FDG accumulation: firstly, standard uptake value (SUV) and secondly dynamic PET. SUV is a poor index of hepatic metabolic function because most hepatic FDG (~75%) is un‐phosphorylated 60‐min postinjection. Hepatic fat is increased in NAFLD but accumulates negligible FDG. Because fat distribution is heterogeneous, maximum pixel SUV is therefore preferred to mean pixel SUV. Computer modelling of dynamic PET dissects the transport constants governing hepatic FDG kinetics but is challenged by the liver's dual blood supply. Graphical analysis is less informative but more robust and will be the preferred clinical approach to measurement of hepatic FDG phosphorylation. Previous dynamic PET studies have ignored hepatic fat and therefore potentially underestimated glucose accumulation in patients with hepatic steatosis. Future work should use graphical analysis of dynamic PET and correction for hepatic fat.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Royal Brompton and Harefield, NHS Foundation Trust, London, UK.
- Department of Nuclear Medicine, King's College Hospital, NHS Foundation Trusts, London, UK.
Zitieren
APA
Keramida, G., & Peters, A. M. (2020). FDG PET/CT of the non‐malignant liver in an increasingly obese world population. Clinical Physiology and Functional Imaging, 40(5), 304-319. https://doi.org/10.1111/cpf.12651
Vancouver
Keramida G, Peters AM. FDG PET/CT of the non‐malignant liver in an increasingly obese world population. Clinical Physiology and Functional Imaging. 2020;40(5):304-319. doi:10.1111/cpf.12651
BibTeX
@article{Keramida2020,
author = {Keramida, Georgia and Peters, A Michael},
title = {FDG PET/CT of the non‐malignant liver in an increasingly obese world population},
journal = {Clinical Physiology and Functional Imaging},
year = {2020},
volume = {40},
number = {5},
pages = {304--319},
doi = {10.1111/cpf.12651}
}
EUVIMED